Xeris Biopharma Holdings, Inc.
XERSQ3 FY2026Period ended Sep 30, 2026
- Fiscal period
- Q3 FY2026
- Period end
- 2026-09-30
- Report due by
- 2026-11-06from the company's last four reports
- Margin metric
- Operating margin
- Status
- Locked
- Scored against
- The 10-Q for the quarter, figures as first reported
- Locks
- Locked Nov 5, 2026, 07:12 ET
Locked
Forecasts locked Nov 5, 2026, 07:12 ET, when EDGAR accepted Xeris Biopharma Holdings, Inc.'s 8-K (2.02 Results of operations), accession 0001867096-26-000114. Anything saved after that second does not count.
Forecasts
Members with a public profile.
No public forecasts on this target.